Shop fda clearance approval supplies
- FDA registered
- ISO 13485
- BBB Accredited A+
Shop at LAC Health
Direct comparison
FDA Clearance vs. Approval Explained
FDA clearance (510(k)) and approval (PMA, or NDA/BLA for drugs) rest on different review standards under different laws. What separates them, in plain terms.
Written and maintained by CASRAI Editorial Board
Last updated
How do 510(k) Clearance, PMA Approval, and De Novo Classification compare side by side?
The table below compares 510(k) Clearance, PMA Approval, and De Novo Classification across 11 dimensions, from outcome term fda uses to where the rules sit in 21 cfr.
Side-by-side comparison
| Dimension | 510(k) Clearance | PMA Approval | De Novo Classification |
|---|---|---|---|
| Outcome term FDA uses | Device is "cleared" | Device is "approved" | Request is "granted" — not a clearance or an approval |
| Product types it applies to | Medical devices only | Medical devices only (drugs/biologics use NDA/BLA approval instead — see FAQ) | Medical devices only |
| Legal basis (FD&C Act) | Section 510(k) | Section 515 | Section 513(f)(2) |
| Review standard | Substantial equivalence to a legally marketed predicate device | Independent demonstration of the device's own safety and effectiveness — no predicate involved | No predicate exists, but device risk is low-to-moderate; FDA creates a new classification rather than comparing to a predicate |
| Typical device risk class | Class I or Class II | Class III (life-supporting, life-sustaining, or otherwise highest-risk) | Results in a new Class I or Class II designation |
| Clinical data usually required? | Not usually — FDA can still request it if the predicate comparison leaves a safety question open | Generally yes — the review standard itself is independent safety-and-effectiveness evidence | Sometimes, depending on the device's risk profile |
| Can the outcome later serve as a predicate for others? | Yes — a cleared device can be cited as a predicate in a future 510(k) | No — PMA-approved devices generally aren't used as 510(k) predicates | Yes — once granted, a De Novo device can serve as a predicate for future 510(k) submissions |
| What the regulation says the outcome does not mean | A substantial-equivalence determination "does not in any way denote official approval of the device"; creating that impression is misbranding (21 CFR 807.97). | This is the outcome FDA itself calls approval: an approval order issued after review of the PMA (21 CFR 814.44). | FDA issues an order granting the De Novo request and publishes a Federal Register notice of the classification order within 30 days (21 CFR 860.260). |
| Can the device be marketed before the outcome? | No. The applicant may not proceed to market until it receives an order declaring the device substantially equivalent (21 CFR 807.100(a)). | No. The applicant must receive FDA approval of its PMA prior to marketing (FDA PMA page). | Devices classified through a granted De Novo request may be marketed (FDA De Novo page). |
| Relationship to establishment registration and listing | Separate obligation. A firm that must register under 21 CFR 807.20 must also submit a 510(k) when 21 CFR 807.81 applies; registration is not the clearance. | Separate obligation. Registration and listing do not substitute for PMA approval. | Separate obligation. Registration and listing do not substitute for a granted De Novo request. |
| Where the rules sit in 21 CFR | Part 807, subpart E | Part 814 | Part 860, subpart D |
Ask CASRAI · free to try
Ask about FDA Clearance vs. Approval Explained
2 free questions a day, no account.
An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.
Common questions
Common questions about 510(k) Clearance vs PMA Approval vs De Novo Classification
Is "FDA cleared" the same as "FDA approved"?
+
No. "Cleared" specifically means a device went through 510(k) premarket notification and FDA found it substantially equivalent to a predicate device already on the market. "Approved" means FDA independently reviewed evidence of the product's own safety and effectiveness with no predicate involved — the outcome for PMA-reviewed devices and for all new drugs and biologics. The two words describe different review standards, not different degrees of the same thing, and using them interchangeably is a factual error in research, regulatory, or grant documentation.
Do drugs and biologics ever get "FDA clearance"?
+
No. Clearance is 510(k) terminology and applies only to medical devices. New drugs are reviewed and approved under a New Drug Application (NDA); biologics are reviewed and approved (technically "licensed") under a Biologics License Application (BLA). A drug or biologic is described as FDA-approved, never FDA-cleared.
What is FDA De Novo classification, and is it a clearance or an approval?
+
Neither. De Novo is a pathway for a novel, low-to-moderate-risk device that has no legally marketed predicate to compare against, which rules out 510(k), but that doesn't warrant the full evidentiary burden of PMA given its risk level. FDA grants the De Novo request and creates a new device classification; that outcome is described as "granted," not as cleared or approved. A granted De Novo device can then itself become a predicate for future 510(k) submissions.
Which pathway applies to laboratory and diagnostic equipment used in a research setting?
+
It depends on the specific device's risk classification, exactly as for any other medical device. Many lab-based in vitro diagnostic (IVD) instruments and test systems go through 510(k) clearance; higher-risk IVDs and novel diagnostic technologies may require PMA approval or De Novo classification instead. The classification determines the pathway, not the setting the device is used in.
Who in a research organization actually needs to know this distinction?
+
Regulatory affairs and compliance staff drafting or reviewing submissions and consent language; IRB coordinators evaluating whether a study device's marketing status affects risk classification or informed-consent disclosures; procurement and lab-equipment managers confirming a purchased instrument's actual FDA status before it's used in a study; and grant/proposal writers who need to describe a device's regulatory status accurately rather than using "approved" as a generic stand-in for any FDA marketing authorization.
What is the difference between FDA registered, listed, cleared, approved and granted?
+
They are five different things. "Registered" means the owner or operator of a device establishment has given FDA its establishment information, and "listed" means the devices it commercially distributes have been reported to FDA, both under 21 CFR 807.20; FDA says registration and listing provides it with the location of device establishments and the devices made there. "Cleared" is the outcome of a 510(k): FDA issues an order declaring the device substantially equivalent to a legally marketed predicate (21 CFR 807.100). "Approved" is the outcome of a PMA, issued as an approval order for a Class III device (21 CFR 814.44). "Granted" is the word for a De Novo request that FDA grants (21 CFR 860.260). Only the last three are premarket outcomes; registration and listing are not.
Does "FDA registered" mean a product is FDA approved?
+
No. 21 CFR 807.39 states that registration of a device establishment, or assignment of a registration number, "does not in any way denote approval of the establishment or its products," and that any representation creating an impression of official approval because of registration or a registration number is misleading and constitutes misbranding.
Can a 510(k)-cleared device be called "FDA approved"?
+
Not accurately. 21 CFR 807.97 states that a substantial-equivalence determination does not in any way denote official approval, and that any representation creating an impression of official approval because of complying with the premarket notification regulations is misleading and constitutes misbranding. "FDA cleared" is the accurate term for a device that went through 510(k).
What may a distributor say about a product's FDA status, and what should it avoid?
+
Based on the regulations above: a distributor can state the specific status that applies (for example 510(k) cleared, PMA approved, or De Novo granted) and should avoid wording that implies official approval from registration, a registration number, or a 510(k). A practical check is to confirm the status against FDA's own records, such as the 510(k) database or the Registration and Listing database, before repeating it; see our guides on reading those records. This is general regulatory information, not legal advice; have regulatory counsel review marketing claims.
When does each pathway apply: PMA, 510(k) or De Novo?
+
PMA applies to Class III devices, which FDA describes as those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury; general and special controls alone are considered insufficient for them (FDA PMA page). A 510(k) is the route when a legally marketed predicate exists (21 CFR 807.81). De Novo is the route for novel devices where general controls, or general and special controls, provide reasonable assurance of safety and effectiveness but no legally marketed predicate exists (FDA De Novo page).
Which sources were used for the registered, listed, cleared, approved and granted comparison?
+
Checked 2026-10-30. 21 CFR 807.20: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-B/section-807.20 | 21 CFR 807.39: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-C/section-807.39 | 21 CFR 807.81: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-E/section-807.81 | 21 CFR 807.97: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-E/section-807.97 | 21 CFR 807.100: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807/subpart-E/section-807.100 | 21 CFR 814.44: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-814/subpart-B/section-814.44 | 21 CFR 860.260: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-860/subpart-D/section-860.260 | FDA Device Registration and Listing: https://www.fda.gov/medical-devices/how-study-and-market-your-device/device-registration-and-listing | FDA 510(k) Clearances: https://www.fda.gov/medical-devices/device-approvals-and-clearances/510k-clearances | FDA Premarket Approval (PMA): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma | FDA De Novo Classification Request: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request
Going deeper







